2022 Emerging RNA Drugs and Smart Manufacturing in Precision Medicine Forum
- 活動類型：講座研討
- 瀏覽次數：2365
- 活動詳細說明
RNA-based therapeutics are novel medications, serving as next-generation alternatives and offering unique opportunities to treat a broad scope of diseases with a significant success in cancer over the past decade. In addition, from perspectives on pandemic prevention, mRNA vaccines have been developed as well and widely harnessed against COVID-19. Therefore, there is growing interest drawn globally in this new class of therapeutics.
Although development of RNA drugs faces unparalleled challenges, many strategies have been built to improve RNA metabolic stability and intracellular delivery, of which smart manufacturing is the most critical when it comes to clinical development and navigating the regulatory pathways. To expedite the biomedical development with COVID’s viral evolution, facilitate networking and in turn co-development between the participants, we are going to have pharmaceutical experts and professionals in this forum sharing the latest trends in this emerging field.
TIME： 16:00-18:00 PM, 17th, March 2022 (TW)
09:00-11:00 AM, 17th, March 2022 (CET)
* Powered by Webex or Equivalent with Online Registration Required in Advance
Supervised by
Industrial Development Bureau, MOEA (IDB)
Organized by
Europe-Taiwan Biotech Association (ETBA)、
Development Center for Biotechnology (DCB)、
Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO)
Agenda
Time
Session
Host / Moderator / Speaker
16:00-16:10 (TW)
9:00-9:10 (CET)
Opening Remarks
Development Center for Biotechnology Europe-Taiwan Biotech Association
16:10-16:30 (TW)
9:10-9:30 (CET)
Preclinical Development of ASOs, Challenges and Opportunities
Karl-Johan Leuchowius, Ph.D.
Associate Principal Scientist
AstraZeneca plc.
16:30-16:50 (TW)
9:30-9:50 (CET)
Lipid Nanoparticles for RNA Drugs: Before and After COVID-19
Tsuimin Tsai, Ph.D.
President
FormuRx Pharmaceuticals Co., Ltd.
16:50-17:10 (TW)
9:50-10:10 (CET)
Resetting the Horizon of Cardiovascular Disease with RNA Therapies
Wendy Liu, M.D.
Medical Lead, ASCVD
Novartis Taiwan Co., Ltd.
17:10-17:30 (TW)
10:10-10:30 (CET)
The Opportunity and Challenges of mRNA Manufacturing
Chih Jung Chang, Ph.D.
COO & Senior Vice President
EirGenix, Inc.
17:30-17:55 (TW)
10:30-10:55 (CET)
Panel Discussion
Moderator
Tess Lu, Ph.D.
Head of Research
Ochre Bio Taiwan Ltd
Panelists
- Karl-Johan Leuchowius Ph.D., AstraZeneca
- Tsuimin Tsai, Ph.D., FormuRx
- Wendy Liu, M.D., Novartis
- Chih Jung Chang, Ph.D., EirGenix
17:55-18:00 (TW)
10:55-11:00 (CET)
Closing Remarks
Michael Huang, Ph.D.
Vice President
Development Center for Biotechnology
All Rights Reserved by the Organizers to Change or Terminate the Event.
Advertised by Industrial Development Bureau, Ministry of Economic Affairs
- 附加檔案